With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.98977-34-5,1-tert-Butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate,as a common compound, the synthetic route is as follows.,98977-34-5
1 -(1 , 1 -Dimethylethyl) 3-ethyl 4-oxo-1 ,3-piperidinedicarboxylate (Intermediate 1 , 380.48 g, 1.40 moles) was dissolved in toluene (2.97 Kg). The solution was stirred for 10 mins and then cooled to -7 0C and then treated with N,N-diisopropylethylamine (271.56 g, 2.10 mol) while maintaining the reaction below -7 0C. After stirring the reaction mixture for approximately 10 minutes, trifluoromethanesulfonic anhydride (436.29 g, 1.55 mol) was added while maintaining the temperature below 5 0C. The reaction mixture was stirred at 1 0C for 31 minutes. The product was used in the next step without purification (see preparation of Intermediate 3); HPLC: Rt= 2.69 min (HPLC instrument Agilent 1 100 Series analysis performed on a Agilent Zorbax SB C18 (50×3.0 mm, 1.8um), mobile phase: water:acetonitrile:TFA (0.05%), gradient from 0 to 95% in 2.5 min, hold for 0.2 min, then re-equilibrate; T=60; flow= 1.5 mL/min)
The synthetic route of 98977-34-5 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; GLAXO GROUP LIMITED; WO2009/109608; (2009); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem